Bristol-Myers Squibb Company Beats Forecast, on Lower Costs, Taxes

Reuters -- Bristol-Myers Squibb Co (BMY.N) reported on Thursday better than expected second-quarter earnings, helped by cost controls, lower taxes and higher sales of its arthritis and cancer treatments.

MORE ON THIS TOPIC